Oncology

Latest News

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com

Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

By Jared Kaltwasser

June 13th 2025

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com

FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg

Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

By Giuliana Grossi

June 12th 2025

AJMC

Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

By Brigham Walker, PhD
Lalan Wilfong, MD

June 11th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com

C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

By Jared Kaltwasser

June 7th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

October 28th 2014

From Diagnostics to Cancer Drug Costs, Nothing's Off Limits at AJMCLive's Patient-Centered Oncology Care

The toughest topics in cancer care will be on tap November 13-14, 2014, in Baltimore, Maryland, when AJMCLive presents Patient-Centered Oncology Care. If you've followed the discussion among pharmaceutical leaders, oncologists, and payers over access to care, you'll want to join stakeholders to discuss how to ensure patients get what they need while controlling costs.

October 28th 2014

Friction Between Health Plans, Pharma Grows Over Specialty Drugs

Mary K. Caffrey

The war of words between managed care and pharmaceutical manufacturers, which began when Gilead set the price for its drug to treat the hepatitis C virus (HCV), has taken off in October with the reclassification of a trio of cancer drugs from Genentech. Growth in the "specialty pharma" sector, where prices are rising much faster than drug prices generally, has drawn concern from payers and the umbrella group that represents them, while the trade group that represents drugmakers is pushing back against critics, saying that it faces challenges in bringing life-saving therapies to market.

October 27th 2014

Breakthrough Designation for Merck's Keytruda in NSCLC

Recently approved as second-line treatment of metastatic melanoma, following resistance to ipilimumab, the FDA has now designated Keytruda as breakthrough therapy to treat EGFR-mutation and ALK-rearrangement negative NSCLC patients who have pr0gressed following platinum-based therapy.

October 27th 2014

Breast Cancer Risk Increased Following Chest Irradiation in Children

Radiation exposure due to chest irradiation in women who had childhood Wilms tumor increased their susceptibility to developing breast cancer later in life.

October 27th 2014

Merck's Rapid Strides With Pembrolizumab

Surabhi Dangi-Garimella, PhD

Today, Merck announced that Keytruda has been granted breakthrough therapy designation for treating patients with epidermal growth factor receptor mutation-negative and anaplastic lymphoma kinase rearrangement-negative non-small cell lung cancer (NSCLC).

October 27th 2014

Scientists Identify a Novel Wnt Signaling Regulator in Colorectal and Endometrial Cancers

The gene mutation in RNF43, previously missed in The Cancer Genome Atlas study, was identified in 20% of colorectal and endometrial cancers.

October 26th 2014

Evidence Shows Improved OS With Delayed Radiation Following Glioblastoma Surgery

The UCSF study identified a window of 30 to 35 days post surgery, following surgery in patients with glioblastoma multiforme, when delayed radiation significantly improved OS and PFS.

October 26th 2014

Nanotechnology Can Aid Early Cancer Diagnosis

This novel fluorescent imaging technique uses shortwave IR, which has much better tissue penetration than near-IR currently used in imaging.

October 26th 2014

In the Literature: A Speech Gene Prevents Breast Cancer Metastasis

The study, published in Cell Stem Cell, identified a microRNA-mediated inhibitory pathway that repressed expression of the speech and language gene FOXP2, promoting metastases of breast cancer cells to distant sites.

October 25th 2014

Quality of Care Takes Precedence for Breast Cancer Patients in New Jersey

Horizon BCBS partners with RCCA to improve quality of care for breast cancer patients by evaluating their molecular subtype before administering treatment.

October 25th 2014

MIT Scientists Develop A Rapid Modeling Technique for Cancer Gene Mutations

The group, led by Koch Institute director Tyler Jacks, used CRISPR to generate mutant genes that were then packaged into enteroviruses that were used to infect target organs in mice. This is a much faster process than the traditional method that need crossing genetically-engineered mice.

October 24th 2014

VeriStrat Proteomic Test Approved by NCCN for Inclusion in NSCLC Treatment

NCCN recommended the diagnostic proteomic test to identify patients who can receive erlotinib as second-line therapy.

October 23rd 2014

Collaborative Model Succeeds in Reducing Cancer Patient Readmissions

Oncologists and palliative care specialists at Duke University Hospital worked together in patient care, resulting in a 23% reduction in patient readmission within a week of discharge.

October 22nd 2014

Everolimus Under FDA Scrutiny For Potential Risk

Everolimus has been added to FDA's Adverse Event Reporting System due to a possible risk of hypertension.

October 21st 2014

Fast Track for Taiho Oncology's mCRC Molecule

Taiho Oncology, Inc, announced that the FDA granted Fast Track designation for an oral combination anticancer drug under investigation for the treatment of refractory metastatic colorectal cancer.

October 21st 2014

In the Literature: New Lead in Treating ALL

The paper, published in Nature, has identified a "switch" that can be inhibited to restrict tumor growth.

October 20th 2014

A SNP That Affords Protection From Breast Cancer Identified

The study, published in the journal Nature Communications, identified the single nucleotide polymorphism near the coding region of the estrogen receptor ESR1 among Latina women.

October 20th 2014

Including Panobinostat Improves PFS in Multiple Myeloma

Including panobinostat in a regimen that included bortezomib and dexamethasone improved median PFS to 11.9 months as compared with 8.08 months in the control arm.

October 19th 2014

Success of Medicare's Prescription-Subsidy Program Among Low-Income Women

A study presented at ASCO's Quality Care Symposium in Boston found increased medication adherence to prevent breast cancer recurrence in those availing of the subsidies.

October 18th 2014

CMS Issues Draft Coverage Decision For Prostate Cancer Test by GenomeDX

The Decipher test is intended for use in men who have undergone radical prostatectomy and are at a high risk of disease recurrence.

October 18th 2014

Janssen's Imbruvica Approved by the European Commission

Imbruvica (ibrutinib) is a first-in-class BTK inhibitor with potential for treating blood cancer, indicated for use in MCL and CLL patients.

October 18th 2014

Exact Sciences' Cologuard Receives CMS National Coverage

The non-invasive nature of the test makes it a very attractive alternative to the uncomfortable colonoscopy used to detect colorectal cancer. In a New England Journal of Medicine study of 10,000 patients, the test identified 92% of colorectal cancers in average-risk patients and 42% of polyps.

October 17th 2014

Roche Joins the Immuno-oncology Front With a PD-L1 inhibitor

While the current approved immuno-oncolgy drugs have been approved for melanoma, Roche has also been evaluating their new molecule in triple-negative breast cancer. The results will be presented at the San Antonio Breast Cancer Symposium.

October 16th 2014

Exciting Clinical Results With Novartis' Leukemia Immune Therapy

The regimen, based on reprogramming the patient's immune T cells to attack the cancer cells, led to the disappearance of cancer in 90 percent of patients, according to a study published in the New England Journal of Medicine.

October 15th 2014

After Roche, Celgene Faces Value Push-Back From NICE

After Roche saw 2 product rejects a few weeks back from NICE, based on a value argument, Celgene is in a similar boat with it's multiple myeloma drug pomalidomide.

October 14th 2014

Study Identifies Gender Bias in HPV Vaccination

Fewer than 15% of physicians routinely recommend HPV vaccination to male patients, according to the study published in the journal Cancer Epidemiology, Biomarkers & Prevention.

October 14th 2014

ASCO Endorses CAP/IASLC/AMP Guideline on Molecular Testing for Lung Cancer

The American Society of Clinical Oncology has endorsed the joint guidelines established by the 3 Associations to help physicians make evidence-based decisions when selecting patients to administer some of the targeted therapies developed for lung cancer.

October 13th 2014

Transition to Managed Care Proves Rough for Ohio Dual Eligibles, Reports Say

Mary K. Caffrey

Ohio is the latest state to experience a rough transition to managed care in its Medicaid program, according to weekend reports. Delayed payments and service disruptions to fragile patients are among the complaints. Kentucky had a similar bumpy start when it changed to Medicaid managed care in 2011, and Kansas has had many problems recently.

October 13th 2014

BMS' PD-1 Inhibitor, Nivolumab, to be Evaluated With Jansenn's Ibrutinib in NHL

Opdivo (nivolumab), which was approved in Japan in July 2014, is being globally developed for evaluation in non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), head and neck cancer, glioblastoma, as well as NHL.

October 13th 2014

Priority Review for Pfizer's Palbociclib in Patients with Advanced Breast Cancer

The NDA submitted by Pfizer requests approval of palbociclib as a first-line therapy in combination with letrozole for ER+, HER2- advanced breast cancer.

...

149 150 151 152 153 154 155 156 157

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions